Direct in vitro selection of a 2'-O-methyl aptamer to VEGF.

Aptamers (protein binding oligonucleotides) have potential as a new class of targeted therapeutics. For applications requiring chronic systemic administration, aptamers must achieve high-affinity target binding while simultaneously retaining high in vivo stability, tolerability, and ease of chemical synthesis. To this end, we describe a method for generating aptamers composed entirely of 2'-O-methyl nucleotides (mRmY). We present conditions under which 2'-O-methyl transcripts can be generated directly and use these conditions to select a fully 2'-O-methyl aptamer from a library of 3 x 10(15) unique 2'-O-methyl transcripts. This aptamer, ARC245, is 23 nucleotides in length, binds to vascular endothelial growth factor (VEGF) with a Kd of 2 nM, and inhibits VEGF activity in cellular assays. Notably, ARC245 is so stable that degradation cannot be detected after 96 hr in plasma at 37 degrees C or after autoclaving at 125 degrees C. We believe ARC245 has considerable potential as an antiangiogenesis therapeutic.

[1]  R. Kuchta,et al.  Polymerization of 2′-fluoro- and 2′-O-methyl-dNTPs by human DNA polymerase α, polymerase γ, and primase , 2000 .

[2]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[3]  M Yarus,et al.  Diversity of oligonucleotide functions. , 1995, Annual review of biochemistry.

[4]  O. Uhlenbeck,et al.  Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates. , 1987, Nucleic acids research.

[5]  P. V. Hippel,et al.  An Integrated Model of the Transcription Complex in Elongation, Termination, and Editing , 1998 .

[6]  P. V. von Hippel,et al.  Protein-nucleic acid interactions in transcription: a molecular analysis. , 1984, Annual review of biochemistry.

[7]  Sheela M. Waugh,et al.  2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.

[8]  A. Ellington,et al.  Evolution of a T7 RNA polymerase variant that transcribes 2′-O-methyl RNA , 2004, Nature Biotechnology.

[9]  Thomas A. Steitz,et al.  Structural Basis for the Transition from Initiation to Elongation Transcription in T7 RNA Polymerase , 2002, Science.

[10]  J. Steitz,et al.  Sno Storm in the Nucleolus: New Roles for Myriad Small RNPs , 1997, Cell.

[11]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[12]  A. Levin,et al.  Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. , 2001, The Journal of pharmacology and experimental therapeutics.

[13]  M. Yarus,et al.  On the properties and utility of a membrane filter assay in the study of isoleucyl-tRNA synthetase. , 1970, Analytical biochemistry.

[14]  A. Schmidt,et al.  Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression. , 1999, Methods in enzymology.

[15]  R. Sousa,et al.  Efficient synthesis of nucleic acids heavily modified with non-canonical ribose 2'-groups using a mutantT7 RNA polymerase (RNAP). , 1999, Nucleic acids research.

[16]  A. Radeghieri,et al.  Expanding the substrate repertoire of a DNA polymerase by directed evolution. , 2004, Journal of the American Chemical Society.

[17]  N. Janjić,et al.  Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. , 1995, Chemistry & biology.

[18]  F. Kabbinavar,et al.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Szostak,et al.  In vitro selection of functional nucleic acids. , 1999, Annual review of biochemistry.

[20]  G. F. Joyce,et al.  Randomization of genes by PCR mutagenesis. , 1992, PCR methods and applications.

[21]  S. Gudima,et al.  Synthesis of mixed ribo/deoxyribopolynucleotides by mutant T7 RNA polymerase , 1998 .

[22]  Lois E. H. Smith,et al.  Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Sousa,et al.  A Y639F/H784A T7 RNA polymerase double mutant displays superior properties for synthesizing RNAs with non-canonical NTPs. , 2002, Nucleic acids research.

[24]  L. Ellis,et al.  Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin™) to chemotherapy improves survival in metastatic colorectal cancer , 2003 .

[25]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[26]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.